Friday, October 11, 2019
WuXi AppTec, BioSolveIT Introduce New Chemical Space of Tangible Molecules
WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi.
Largely built from WuXi AppTec’s library of novel drug-like scaffolds, GalaXi offers access to billions of compounds to drug discoverers around the world. Due to a carefully selected building block supply and proven chemistry, the GalaXi space consists of molecules that can be quickly synthesized on demand.
Novel molecular entities are in high demand to combat diseases such as cancer, bacterial and viral infections, as well as illnesses of the central nervous system. Over decades, traditional compound libraries containing millions of compounds have been collected and curated. However, many more compounds, though synthetically feasible, have traditionally been inaccessible due to physical and informatic limitations. The GalaXi space is a combination of WuXi AppTec’s chemistry expertise and BioSolveIT’s cutting edge software technologies, resulting in a chemical space housing billions of virtual molecules that can be mined within minutes and synthesized within a few weeks.
The game-changing element of this system lies in the design of a virtual chemical space that is both vast and practical in its synthetic feasibility. Navigation of GalaXi relies on clever algorithms that account for the chemicals and chemistry expertise to turn ideas into matter. Not only is the GalaXi orders of magnitude larger than traditional libraries, but also turn-around times and costs of custom synthesis are drastically reduced.
‘We used to be able to screen millions of compounds in seconds, but access to billions of compounds in minutes is just amazing,’ said Dr. Steve Yang, Executive Vice President and Chief Business Officer of WuXi AppTec. ‘This is exactly what our clients need. The pressure on research to come up with novel ideas is indeed enormous, both in terms of time and cost. With GalaXi we take a large step forward in improving the productivity of new drug discovery and bring new medicines to patients faster.’
https://www.marketscreener.com/WUXI-APPTEC-CO-LTD-44403583/news/WuXi-AppTec-Research-Service-Division-and-BioSolveIT-Introduce-GalaXi-a-Vast-New-Chemical-Space-o-29367643/
Largely built from WuXi AppTec’s library of novel drug-like scaffolds, GalaXi offers access to billions of compounds to drug discoverers around the world. Due to a carefully selected building block supply and proven chemistry, the GalaXi space consists of molecules that can be quickly synthesized on demand.
Novel molecular entities are in high demand to combat diseases such as cancer, bacterial and viral infections, as well as illnesses of the central nervous system. Over decades, traditional compound libraries containing millions of compounds have been collected and curated. However, many more compounds, though synthetically feasible, have traditionally been inaccessible due to physical and informatic limitations. The GalaXi space is a combination of WuXi AppTec’s chemistry expertise and BioSolveIT’s cutting edge software technologies, resulting in a chemical space housing billions of virtual molecules that can be mined within minutes and synthesized within a few weeks.
The game-changing element of this system lies in the design of a virtual chemical space that is both vast and practical in its synthetic feasibility. Navigation of GalaXi relies on clever algorithms that account for the chemicals and chemistry expertise to turn ideas into matter. Not only is the GalaXi orders of magnitude larger than traditional libraries, but also turn-around times and costs of custom synthesis are drastically reduced.
‘We used to be able to screen millions of compounds in seconds, but access to billions of compounds in minutes is just amazing,’ said Dr. Steve Yang, Executive Vice President and Chief Business Officer of WuXi AppTec. ‘This is exactly what our clients need. The pressure on research to come up with novel ideas is indeed enormous, both in terms of time and cost. With GalaXi we take a large step forward in improving the productivity of new drug discovery and bring new medicines to patients faster.’
https://www.marketscreener.com/WUXI-APPTEC-CO-LTD-44403583/news/WuXi-AppTec-Research-Service-Division-and-BioSolveIT-Introduce-GalaXi-a-Vast-New-Chemical-Space-o-29367643/
OxyContin maker Purdue begins showdown to halt opioid lawsuits
OxyContin maker Purdue Pharma LP will ask a U.S. Bankruptcy Judge on Friday to pause litigation against the company and its owners over the objections of U.S. states that allege the company is trying to protect the controlling Sackler family.
Purdue’s request promises to be one of the most contentious of the
company’s Chapter 11 bankruptcy case, which was filed in September to
try to implement a settlement proposal it values at more than $10
billion.
Privately-held Purdue said last month it needed to pause more than 2,600 lawsuits so the company can reduce legal costs and try to win over more plaintiffs to its proposed deal.
The lawsuits accuse Purdue and the Sacklers of fueling a public health crisis by aggressively marketing opioids while downplaying their overdose risks, contributing to some 400,000 deaths from 1999 to 2017, according to U.S. statistics.
The company said it has the support of a majority of the local governments that brought the bulk of the lawsuits, although at least 24 states oppose the deal.
Massachusetts Attorney General Maura Healey, a settlement opponent, has accused Purdue of protecting the billionaire Sacklers.
The family has not filed for bankruptcy protection, which generally automatically pauses litigation but also imposes obligations to open financial records. The family has pledged to contribute at least $3 billion to the settlement and will relinquish ownership of Purdue to the plaintiffs.
States opposed to the settlement disclosed in a court filing last week that Purdue steered about $12 billion in profits to the Sacklers.
At a Thursday court hearing, a lawyer for Purdue challenged that characterization and said it covered a period dating back to 1995, and was disclosed to plaintiffs a year ago. “The $12 billion figure is in fact not new at all,” said Marshall Huebner, a Davis Polk & Wardwell lawyer who represents Purdue.
Among other things, Purdue will have to convince U.S. Bankruptcy Judge Robert Drain in White Plains, New York, that pausing litigation is in the public interest.
Holdout states said their cases are aimed in part at uncovering the extent of the company’s misconduct.
“This court should not strip the states of their core function to enforce their own regulatory laws in their own courts and administrative bodies,” said a filing last week by the states opposed to the deal.
Privately-held Purdue said last month it needed to pause more than 2,600 lawsuits so the company can reduce legal costs and try to win over more plaintiffs to its proposed deal.
The lawsuits accuse Purdue and the Sacklers of fueling a public health crisis by aggressively marketing opioids while downplaying their overdose risks, contributing to some 400,000 deaths from 1999 to 2017, according to U.S. statistics.
The company said it has the support of a majority of the local governments that brought the bulk of the lawsuits, although at least 24 states oppose the deal.
Massachusetts Attorney General Maura Healey, a settlement opponent, has accused Purdue of protecting the billionaire Sacklers.
The family has not filed for bankruptcy protection, which generally automatically pauses litigation but also imposes obligations to open financial records. The family has pledged to contribute at least $3 billion to the settlement and will relinquish ownership of Purdue to the plaintiffs.
States opposed to the settlement disclosed in a court filing last week that Purdue steered about $12 billion in profits to the Sacklers.
At a Thursday court hearing, a lawyer for Purdue challenged that characterization and said it covered a period dating back to 1995, and was disclosed to plaintiffs a year ago. “The $12 billion figure is in fact not new at all,” said Marshall Huebner, a Davis Polk & Wardwell lawyer who represents Purdue.
Among other things, Purdue will have to convince U.S. Bankruptcy Judge Robert Drain in White Plains, New York, that pausing litigation is in the public interest.
Holdout states said their cases are aimed in part at uncovering the extent of the company’s misconduct.
“This court should not strip the states of their core function to enforce their own regulatory laws in their own courts and administrative bodies,” said a filing last week by the states opposed to the deal.
https://www.marketscreener.com/news/OxyContin-maker-Purdue-begins-showdown-to-halt-opioid-lawsuits–29366729/?countview=0
‘Historically cheap’ J&J a buy – Bernstein
Legal overhangs on the share price are overdone, says analyst Lee Hambright, noting a 13% decline from the 52-week high.
Settlements in the $50B range are a worst-case
scenario, he says, yet are already priced in. A more likely range is
$10B-$12B, he argues – $5B for opioids, $5B for talc, and $800M for
Risperdal.
As for valuation, J&J (NYSE:JNJ)
is trading at a 17% discount vs. a 12% premium to the S&P 500 at
the end of last year – that’s almost two standard deviations below the
long-term average.
He upgrades to Outperform and boosts his price target to $155 from $148. Shares are up 1.5% early to $131.
The Seeking Alpha Authors average rating is Bullish and the Quant Rating Neutral.
Previously: Bernstein sees 20% upside in J&J in premarket analyst action (Oct. 11)
https://seekingalpha.com/news/3505267-historically-cheap-j-and-j-buy-bernsteinVir Bio prices IPO at $20
Vir Biotechnology (VIR) has priced its initial public offering of 7,142,858 common shares at $20.00/share, for expected gross proceeds of ~$142.9M.
Underwriters over-allotment is an additional 1,071,428 shares.
The shares are expected to begin trading on Nasdaq today.
Net proceeds will be used to complete and advance clinical trials, for working capital and other general corporate purposes.
Closing date is October 16.
https://seekingalpha.com/news/3505190-vir-bio-prices-ipo-20Gilead and Galapagos’ filgotinib shows durable effect in late-stage RA studies
Gilead Sciences (NASDAQ:GILD) and licensor Galapagos NV (NASDAQ:GLPG) announce long-term results from Phase 3 clinical trials, FINCH 1 and FINCH 2, evaluating JAK1 inhibitor filgotinib in patients with moderately-to-severely active rheumatoid arthritis (RA).
Data at week 52 are consistent with the safety,
tolerability and efficacy results observed at weeks 12 and 24. Detailed
results will be presented at a future medical conference.
Marketing applications are currently under review
in Europe and Japan. Gilead plans to file an NDA in the U.S. later this
quarter.
GILD is up 1% and GLPG is up 2% premarket, both on light volume.
https://seekingalpha.com/news/3505212-gilead-galapagos-filgotinib-shows-durable-effect-late-stage-ra-studies
Subscribe to:
Posts (Atom)